Key Highlights

  • Shares were down 9.21% to USD 13.50 in pre-market trading on November 4, 2026.
  • Third quarter net sales were USD 205.9 million, down from USD 213.7 million a year earlier.
  • Core Nutritional active customers fell 8% to 356,000 from 388,000.
  • Fiscal 2026 adjusted diluted EPS guidance was cut to USD 0.55 from USD 0.76.
  • Cash was USD 178.9 million with no Debt outstanding at the end of the quarter.

What Moved USANA Before the Open (down USD 1.37, 9.21%)

USANA Health Sciences, Inc. (NYSE:USNA) was down 9.21%, or USD 1.37, to USD 13.50 in pre-market trading on November 4, 2026, measured against the November 3, 2026 close. The catalyst is the company's third quarter 2026 Earnings release, issued on November 3, 2026, which showed lower sales, a shrinking core customer base and a reduced full year outlook. Chief Executive Kevin Guest described the quarter as mixed.

The Quarter and the Revised Outlook

For the fiscal quarter ended October 3, 2026, net sales were USD 205.9 million, down 3.6% from USD 213.7 million. The company swung to an operating loss of USD 1.4 million from Operating Income of USD 1.2 million. Net loss attributable to USANA was USD 5.6 million, or USD 0.30 per diluted share, compared with USD 6.5 million, or USD 0.36, a year earlier. Adjusted diluted EPS was a loss of USD 0.11 against a loss of USD 0.15, and adjusted EBITDA was USD 12.1 million against USD 13.8 million, down 13%.

For fiscal 2026, the company now expects net sales approaching USD 900 million, from USD 910 million before. Net loss is guided to USD 16 million, or USD 0.90 per share, from USD 11 million, or USD 0.61. Adjusted diluted EPS guidance moved to USD 0.55 from USD 0.76, and adjusted EBITDA to USD 77 million from USD 80.5 million as corrected. The company also corrected second quarter adjusted EBITDA to USD 21.7 million from USD 27.8 million.

Business Background and Segment Detail

USANA develops and sells science based nutritional supplements and personal care products through a direct selling network, and also operates the Hiya children's vitamin subscription Business and Rise Wellness.

Core Nutritional net sales were USD 170.7 million, down 3.1%, and active customers fell 8% to 356,000 from 388,000. Hiya net sales rose 2.3% to USD 31.5 million, with active monthly subscribers at 195,500 against 193,400, and the company said Target and Amazon sales more than doubled from the second quarter. Rise Wellness sales fell 44.8% to USD 3.6 million.

Balance Sheet and Risks

Cash and equivalents were USD 178.9 million, and the USD 14 million line of Credit outstanding at January 3, 2026 has been repaid, leaving no debt. Free Cash Flow was USD 8.4 million in the quarter and USD 35.7 million year to date. There were no share repurchases in the quarter.

The main risks are the falling Core Nutritional customer count, a large Goodwill Impairment already taken at Hiya, and the second quarter correction, which raises questions about reporting precision.

What to Watch Next

The fourth quarter is the next test. Management expects sequential improvement in Hiya net sales and adjusted EBITDA, with further Hiya updates due in early 2027. Core customer trends, any resumption of Buybacks and the level of cost savings will shape sentiment.